Among these, axitinib, a highly selective VEGF receptor inhibitor, has been reported to have anti-tumour activity in combination with the PD-L1 inhibitor avelumab in patients with advanced HCC [59,60]. The gene discussed is CD274; the disease is hepatocellular carcinoma.